Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have received a consensus rating of “Hold” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $28.1429.

KMTS has been the subject of several analyst reports. BTIG Research reiterated a “buy” rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research note on Wednesday, September 2nd. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 31st. JPMorgan Chase & Co. started coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They set an “overweight” rating and a $30.00 price target for the company. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a research report on Wednesday, July 15th.

Kestra Medical Technologies Price Performance

KMTS opened at $22.85 on Monday. Kestra Medical Technologies has a 1 year low of $17.34 and a 1 year high of $30.00. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41. The company has a market capitalization of $1.34 billion, a price-to-earnings ratio of -9.44 and a beta of 0.62. The firm’s fifty day moving average price is $25.34 and its two-hundred day moving average price is $22.68.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million during the quarter. As a group, analysts anticipate that Kestra Medical Technologies will post -2.29 earnings per share for the current fiscal year.

Trending Headlines about Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra appointed Daniel Finney as Vice President of Research & Development and added him to its executive leadership team. Finney has more than 20 years of Class III medical-device experience and previously led Kestra’s new product development. He will oversee innovation for the Cardiac Recovery System, including strategic partnerships and artificial-intelligence initiatives, providing leadership continuity after the retirement of Phillip Foshee. Kestra Names Daniel Finney Vice President of Research & Development
• Neutral Sentiment: Reported short interest was zero shares as of September 10, unchanged from the prior reporting period. This suggests limited measurable short-selling pressure, but also provides little new information for investors.
• Neutral Sentiment: Analyst expectations remain mixed. BTIG maintains a $32 price target and JPMorgan has a $30 target, while other analysts are more cautious; the reported median target from recent forecasts is $24.50. The upcoming earnings release could prompt additional estimate changes. Kestra earnings preview
• Negative Sentiment: Four directors sold a combined 16,424 shares worth approximately $414,000. The transactions reduced their individual holdings by about 9% to 48%. Because the sales were made to cover tax withholding on vested equity awards, they are less concerning than discretionary selling, though the cluster may weigh on sentiment. SEC insider transaction filings
• Negative Sentiment: Kestra is expected to report a first-quarter loss, adding to concerns about profitability. Its latest reported quarter showed a $0.67 per-share loss, worse than the $0.59 consensus estimate, despite revenue of $28.64 million. Analysts currently forecast a full-year loss of approximately $2.29 per share.

Insider Activity at Kestra Medical Technologies

In related news, insider Brian Webster sold 15,000 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $27.48, for a total value of $412,200.00. Following the transaction, the insider directly owned 460,215 shares of the company’s stock, valued at approximately $12,646,708.20. The trade was a 3.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey Schwartz sold 3,890 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $25.18, for a total transaction of $97,950.20. Following the sale, the director owned 7,019 shares of the company’s stock, valued at $176,738.42. This trade represents a 35.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 239,588 shares of company stock worth $5,802,688. 5.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

Several institutional investors have recently bought and sold shares of the company. Seven Grand Managers LLC bought a new position in shares of Kestra Medical Technologies during the 4th quarter worth $2,652,000. Eventide Asset Management LLC increased its holdings in Kestra Medical Technologies by 5.4% in the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares during the last quarter. Sei Investments Co. raised its stake in Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after acquiring an additional 43,753 shares during the period. UBS Group AG lifted its holdings in Kestra Medical Technologies by 34.9% during the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after purchasing an additional 69,908 shares during the last quarter. Finally, Summit Partners Public Asset Management LLC purchased a new stake in Kestra Medical Technologies during the fourth quarter valued at about $9,282,000.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical device company focused on developing and commercializing technologies for patients at risk of sudden cardiac arrest. The company’s primary product is the ASSURE wearable cardioverter defibrillator, a wearable system designed to continuously monitor a patient’s heart rhythm and deliver an electrical shock when a life-threatening arrhythmia is detected.

The ASSURE system is intended to provide temporary protection for patients who may be at elevated risk of sudden cardiac death but are not yet candidates for, or are awaiting, an implantable cardioverter-defibrillator.